{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:49:03Z","timestamp":1789206543997,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Fujian Science and Technology Department","award":["2023Y0045"],"award-info":[{"award-number":["2023Y0045"]}]},{"name":"the Fujian Science and Technology Department","award":["2023Y0045"],"award-info":[{"award-number":["2023Y0045"]}]},{"name":"the Fujian Science and Technology Department","award":["2023Y0045"],"award-info":[{"award-number":["2023Y0045"]}]},{"name":"the Fujian Science and Technology Department","award":["2023Y0045"],"award-info":[{"award-number":["2023Y0045"]}]},{"name":"the Fujian Science and Technology Department","award":["2023Y0045"],"award-info":[{"award-number":["2023Y0045"]}]},{"name":"the Fujian Science and Technology Department","award":["2023Y0045"],"award-info":[{"award-number":["2023Y0045"]}]},{"name":"the Department of Finance, Fujian Province, China","award":["(2024)881-2024058"],"award-info":[{"award-number":["(2024)881-2024058"]}]},{"name":"the Department of Finance, Fujian Province, China","award":["(2024)881-2024058"],"award-info":[{"award-number":["(2024)881-2024058"]}]},{"name":"the Department of Finance, Fujian Province, China","award":["(2024)881-2024058"],"award-info":[{"award-number":["(2024)881-2024058"]}]},{"name":"the Department of Finance, Fujian Province, China","award":["(2024)881-2024058"],"award-info":[{"award-number":["(2024)881-2024058"]}]},{"name":"the Department of Finance, Fujian Province, China","award":["(2024)881-2024058"],"award-info":[{"award-number":["(2024)881-2024058"]}]},{"name":"the Department of Finance, Fujian Province, China","award":["(2024)881-2024058"],"award-info":[{"award-number":["(2024)881-2024058"]}]},{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2024Y9009"],"award-info":[{"award-number":["2024Y9009"]}]},{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2024Y9009"],"award-info":[{"award-number":["2024Y9009"]}]},{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2024Y9009"],"award-info":[{"award-number":["2024Y9009"]}]},{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2024Y9009"],"award-info":[{"award-number":["2024Y9009"]}]},{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2024Y9009"],"award-info":[{"award-number":["2024Y9009"]}]},{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2024Y9009"],"award-info":[{"award-number":["2024Y9009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-025-02222-4","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:34:08Z","timestamp":1759491248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An ADR pharmaceutical care for severe gastrointestinal bleeding of rivaroxaban in a patient with nonvalvular atrial fibrillation based on TDM and genetic testing: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Youqi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuze","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"19","key":"2222_CR1","first-page":"17","volume":"30","author":"G Lip","year":"2016","unstructured":"Lip G, Fauchier L, Freedman S, Van G, Natale A, Gianni C, Nattel S, Potpara T, Rienstra M, Tse HJNS. Atr Fibrillation. 2016;30(19):17\u201317.","journal-title":"Atr Fibrillation"},{"issue":"8","key":"2222_CR2","first-page":"A290","volume":"71","author":"BK Martinez","year":"2018","unstructured":"Martinez BK, Sood NA, Bunz TJ. Coleman cijjotacoc: effectiveness and safety of apixaban, dabigatran, and Rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. 2018;71(8):A290.","journal-title":"Coleman cijjotacoc: effectiveness and safety of apixaban, dabigatran, and Rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation."},{"key":"2222_CR3","doi-asserted-by":"crossref","unstructured":"Lin Y, Xiong H, Su J, Lin J, Zhou Q, Lin M, Zhao W, Peng FJH. Vessels: effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation. 2022, 37(7):1224\u201331.","DOI":"10.1007\/s00380-022-02021-2"},{"key":"2222_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.thromres.2022.08.007","volume":"218","author":"HN Wen","year":"2022","unstructured":"Wen HN, He QF, Xiang XQ, Jiao Z, Yu JG. Predicting drug-drug interactions with physiologically based pharmacokinetic\/pharmacodynamic modelling and optimal dosing of Apixaban and Rivaroxaban with Dronedarone co-administration. Thromb Res. 2022;218:24\u201334.","journal-title":"Thromb Res"},{"issue":"11","key":"2222_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12111040","volume":"12","author":"LT Ngo","year":"2020","unstructured":"Ngo LT, Yang SY, Tran QT, Kim SK, Chae JWJP. Effects of carbamazepine and phenytoin on pharmacokinetics and pharmacodynamics of Rivaroxaban. Pharmaceutics. 2020;12(11):1040.","journal-title":"Pharmaceutics"},{"key":"2222_CR6","doi-asserted-by":"crossref","unstructured":"Gouin-Thibault I, Delavenne X, Blanchard A, Siguret V, Salem J, Narjoz C, Gaussem P, Beaune P, Funck-Brentano C, Azizi MJJT, et al. Inter-individual variability in Dabigatran and Rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. 2017;15(2):273\u201383.","DOI":"10.1111\/jth.13577"},{"issue":"5","key":"2222_CR7","first-page":"477","volume":"72","author":"L Yi-Cheng","year":"2018","unstructured":"Yi-Cheng L, Shu-Chen C, Yi-Chen H, Chun-Ming S, Feng-Yen L, Nai-Wen T, Chih-Wei C, Yung-Ta K, Kuang-Hsing C. Wan-Ting cjjotacoc: effectiveness and safety of Standard- and Low-Dose Rivaroxaban InAsians with atrial fibrillation. 2018;72(5):477\u201385.","journal-title":"Wan-Ting cjjotacoc: effectiveness and safety of Standard- and Low-Dose Rivaroxaban InAsians with atrial fibrillation."},{"issue":"12","key":"2222_CR8","doi-asserted-by":"publisher","first-page":"e0277744","DOI":"10.1371\/journal.pone.0277744","volume":"17","author":"S Perreault","year":"2022","unstructured":"Perreault S, C\u00f4t\u00e9 R, Dragomir A, White-Guay B, Lenglet A, Dorais M. Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation. PLoS One. 2022;17(12):e0277744.","journal-title":"PLoS One"},{"issue":"7","key":"2222_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.7326\/M23-0675","volume":"176","author":"ZK McQuilten","year":"2023","unstructured":"McQuilten ZK, Thao LTP, Pasricha SR, Artz AS, Bailey M, Chan AT, et al. Effect of low-dose aspirin versus placebo on incidence of anemia in the elderly: a secondary analysis of the aspirin in reducing events in the elderly trial. Ann Intern Med. 2023;176(7):913\u201321.","journal-title":"Ann Intern Med"},{"key":"2222_CR10","doi-asserted-by":"crossref","unstructured":"Siguret V, Abdoul J, Delavenne X, Curis E, Thrombosis, IGhJJo. Haemostasis: Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: modeling and assessing interindividual variability. 2019;17(10):1670\u201382.","DOI":"10.1111\/jth.14541"},{"key":"2222_CR11","doi-asserted-by":"crossref","unstructured":"Gulilat M, Tang A, Gryn SE, Leong-Sit P, Skanes AC, Alfonsi JE, Dresser GK, Henderson SL, Rose RV. Lizotte djjcjoc: interpatient variation in Rivaroxaban and Apixaban plasma concentrations in routine care. 2017:1036\u201343.","DOI":"10.1016\/j.cjca.2017.04.008"},{"key":"2222_CR12","doi-asserted-by":"crossref","unstructured":"Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD. Stein cmjjtjotama: association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper Gastrointestinal tract bleeding. 2018;320(21):2221\u201330.","DOI":"10.1001\/jama.2018.17242"},{"key":"2222_CR13","doi-asserted-by":"crossref","unstructured":"Ingason AB, Hreinsson JP, Lund SH, Bjrnsson EJG. 326 \u2013 Rivaroxaban is associated with higher rates of Gastrointestinal bleeding compared to other Non-Vitamin K anticoagulants: A Population-Based propensity scorematched cohort study. 2019;156(6):S\u201364.","DOI":"10.1016\/S0016-5085(19)36946-X"},{"issue":"1","key":"2222_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2013","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka MJCP. Clinical pharmacokinetic and pharmacodynamic profile of Rivaroxaban. Clin Pharmacokinet. 2013;53(1):1\u201316.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2222_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s11239-020-02326-x","volume":"52","author":"E Kampouraki","year":"2021","unstructured":"Kampouraki E, Abohelaika S, Avery P, Biss T, Murphy P, Wynne H, et al. Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing. J Thromb Thrombolysis. 2021;52(1):170\u20138.","journal-title":"J Thromb Thrombolysis"},{"key":"2222_CR16","doi-asserted-by":"crossref","unstructured":"Lenoir C, Terrier J, Gloor Y, Gosselin P, Daali Y, Combescure C, Desmeules JA, Samer CF, Reny JL. Rollason vjjopm: impact of the genotype and phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban exposure in a Real-World setting. 2022;12(4):526.","DOI":"10.3390\/jpm12040526"},{"key":"2222_CR17","doi-asserted-by":"publisher","first-page":"914842","DOI":"10.3389\/fphar.2022.914842","volume":"13","author":"T Zhao","year":"2022","unstructured":"Zhao T, Li X, Chen Y, Du J, Chen X, Wang D, Wang L, Zhao S, Wang C, Meng Q, et al. Risk assessment and molecular mechanism study of drug-drug interactions between Rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2\/3A4 and BCRP\/P-gp. Front Pharmacol. 2022;13:914842.","journal-title":"Front Pharmacol"},{"key":"2222_CR18","doi-asserted-by":"crossref","unstructured":"Shnayder N, Petrova M, Bochanova E, Zimnitskaya O, Nasyrova R. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J Pers Med. 2021;11(1):37.","DOI":"10.5772\/intechopen.95966"},{"key":"2222_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115058","volume":"165","author":"G Villapalos-Garc\u00eda","year":"2023","unstructured":"Villapalos-Garc\u00eda G, Zubiaur P, Ochoa D, Soria-Chacartegui P, Navares-G\u00f3mez M, Matas M, et al. NAT2 phenotype alters pharmacokinetics of Rivaroxaban in healthy volunteers. Biomed Pharmacother. 2023;165:115058.","journal-title":"Biomed Pharmacother"},{"key":"2222_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70078","author":"D Wang","year":"2025","unstructured":"Wang D, An Y, Zhou X, Chai H, Huo J, Li C, et al. Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct-acting oral anticoagulants. Br J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1002\/bcp.70078.","journal-title":"Br J Clin Pharmacol"},{"key":"2222_CR21","doi-asserted-by":"crossref","unstructured":"Sychev D, Ostroumova O, Cherniaeva M, Shakhgildian N, Mirzaev K, Abdullaev S, Denisenko N, Sozaeva Z, Kachanova A, Gorbatenkova, SJHbp et al. The influence of ABCB1 (rs1045642 and rs4148738) gene polymorphisms on Rivaroxaban pharmacokinetics in patients aged 80 years and older with nonvalvular atrial fibrillation. 2022, 29(5):469\u201380.","DOI":"10.1007\/s40292-022-00536-3"},{"key":"2222_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.639854","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen M, Chen H, Wang FJFP. Influence of ABCB1 gene polymorphism on Rivaroxaban blood concentration and hemorrhagic events in patients with atrial fibrillation. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.639854.","journal-title":"Front Pharmacol"},{"key":"2222_CR23","doi-asserted-by":"crossref","unstructured":"Kuntheavy IL, Youssef D, Pierre F, Jules D. Caroline sjfip: Rivaroxaban-Induced hemorrhage associated with ABCB1 genetic defect. 2016, 7:494.","DOI":"10.3389\/fphar.2016.00494"},{"issue":"30","key":"2222_CR24","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.2174\/1381612824666181018153641","volume":"24","author":"Q Xie","year":"2018","unstructured":"Xie Q, Xiang Q, Mu G, Ma L, Chen S, Zhou S, et al. Effect of ABCB1 genotypes on the pharmacokinetics and clinical outcomes of new oral anticoagulants: a systematic review and meta-analysis. Curr Pharm Des. 2018;24(30):3558\u201365.","journal-title":"Curr Pharm Des"},{"key":"2222_CR25","unstructured":"Haeusler GK, Heidbuchel. Hein, Collins, Ronan, Rowell, Nigel, Potpara, Tatjana SJE-L-: The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. 2018;20(8):1231\u201342."},{"issue":"1","key":"2222_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.31083\/j.rcm2301002","volume":"23","author":"DG Shin","year":"2022","unstructured":"Shin DG, Kim S, Kim YR. Bleeding risk in patients with atrial fibrillation treated with combined anti-platelet and non-vitamin K antagonist oral anticoagulant therapy. Rev Cardiovasc Med. 2022;23(1):2.","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"2222_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.hrthm.2022.09.011","volume":"20","author":"ZA Sporn","year":"2023","unstructured":"Sporn ZA, Berman AN, Daly D, Wasfy JH. Improving guideline-based anticoagulation in atrial fibrillation: a systematic literature review of prospective trials. Heart Rhythm. 2023;20(1):69\u201375.","journal-title":"Heart Rhythm"},{"issue":"5","key":"2222_CR28","first-page":"619","volume":"35","author":"M Proietti","year":"2019","unstructured":"Proietti M, Lane DA, Boriani G, Lip GYH. Stroke prevention, evaluation of bleeding risk, and anticoagulant treatment management in atrial fibrillation contemporary international guidelines. Can J Cardiol. 2019;35(5):619\u201333.","journal-title":"Can J Cardiol"},{"key":"2222_CR29","doi-asserted-by":"crossref","unstructured":"Wells, Philip S, Gebel, Martin, Prins, Martin H, Davidson, Journal BJT. Influence of Statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving Rivaroxaban or standard anticoagulant therapy. 2014;12:26.","DOI":"10.1186\/1477-9560-12-26"},{"issue":"7","key":"2222_CR30","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1177\/10600280211049727","volume":"56","author":"AS Bhagavathula","year":"2022","unstructured":"Bhagavathula AS, Vidyasaga K, Gebreyohannes EA, Tesfaye WJAP. Risk of gastrointestinal bleeding on treatment with statin alone or with concomitant administration of warfarin: a systematic review and meta-analysis of 5.3 million participants. Ann Pharmacother. 2022;56(7):820\u201330.","journal-title":"Ann Pharmacother"},{"key":"2222_CR31","doi-asserted-by":"crossref","unstructured":"Obayo A, Ngunga M, Shah J, Sokwala A, Barasa AJCA. Bleeding complications in patients on new oral anticoagulants for venous thromboembolism in Kenya. 2022;33(4):186\u201392.","DOI":"10.5830\/CVJA-2021-060"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02222-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-025-02222-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02222-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:34:15Z","timestamp":1759491255000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-025-02222-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2222"],"URL":"https:\/\/doi.org\/10.1186\/s12920-025-02222-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3885607\/v1","asserted-by":"object"}]},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"21 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethics Committee of Fuzhou University Affiliated Provincial Hospital and was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent to participate in this study was provided by the participant\u2019s legal guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the individual\u2019s legal guardian for the publication of any potentially identifiable images or data included in this article. A copy of the written consent is available for review by the editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}